{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:49:17Z","timestamp":1777366157179,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lanzhou Institute of Biological Products Co., Ltd (LIBP) of Sinopharm, and Beijing Institute of Biological Products Co., Ltd (BIBP) of Sinopharm."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>NVSI-06-08 is a potential broad-spectrum recombinant COVID-19 vaccine that integrates the antigens from multiple SARS-CoV-2 strains into a single immunogen. Here, we evaluate the safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in BBIBP-CorV recipients in a randomized, double-blind, controlled, phase 2 trial conducted in the United Arab Emirates (NCT05069129). Three groups of healthy adults over 18 years of age (600 participants per group) who have administered two doses of BBIBP-CorV 4-6-month, 7-9-month and &gt;9-month earlier, respectively, are randomized 1:1 to receive either a homologous booster of BBIBP-CorV or a heterologous booster of NVSI-06-08. The incidence of adverse reactions is low, and the overall safety profile is quite similar between two booster regimens. Both Neutralizing and IgG antibodies elicited by NVSI-06-08 booster are significantly higher than those by BBIBP-CorV booster against not only SARS-CoV-2 prototype strain but also multiple variants of concerns (VOCs). Especially, the neutralizing antibody GMT against Omicron variant induced by heterologous NVSI-06-08 booster reaches 367.67, which is substantially greater than that boosted by BBIBP-CorV (GMT: 45.03). In summary, NVSI-06-08 is safe and immunogenic as a booster dose following two doses of BBIBP-CorV, which is immunogenically superior to the homologous boost with another dose of BBIBP-CorV.<\/jats:p>","DOI":"10.1038\/s41467-022-31379-0","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T01:02:40Z","timestamp":1656291760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2180-4158","authenticated-orcid":false,"given":"Nawal Al","family":"Kaabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Kai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Fang","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Guo","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Saif","family":"ElDein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen Sen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue Jun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangfeng","family":"Cong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanadi Mekki","family":"Mekki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5868-7568","authenticated-orcid":false,"given":"Walid","family":"Zaher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1348-9063","authenticated-orcid":false,"given":"Sally","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam","family":"Eltantawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Wei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze Hua","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao Nian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Liang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Yan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-4355","authenticated-orcid":false,"given":"Xiao Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-4290","authenticated-orcid":false,"given":"Guizhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8284-7106","authenticated-orcid":false,"given":"Qi Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"31379_CR1","unstructured":"WHO. Status of COVID-19 vaccines within WHO EUL\/PQ evaluation process. https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/Status_COVID_VAX_23Dec2021.pdf (2022)."},{"key":"31379_CR2","unstructured":"WHO. WHO coronavirus (COVID-19) dashboard. https:\/\/covid19.who.int\/ (2022)."},{"key":"31379_CR3","doi-asserted-by":"publisher","first-page":"2270066","DOI":"10.1002\/advs.202270066","volume":"9","author":"MO Aydogdu","year":"2022","unstructured":"Aydogdu, M. O. et al. Severe acute respiratory syndrome type 2-causing coronavirus: variants and preventive strategies. Adv. Sci. 9, 2270066 (2022).","journal-title":"Adv. Sci."},{"key":"31379_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41577-021-00662-4","volume":"22","author":"M Lipsitch","year":"2022","unstructured":"Lipsitch, M. et al. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat. Rev. Immunol. 22, 57\u201365 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"31379_CR5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1126\/science.abl8487","volume":"374","author":"RK Gupta","year":"2021","unstructured":"Gupta, R. K. & Topol, E. J. COVID-19 vaccine breakthrough infections. Science 374, 1561\u20131562 (2021).","journal-title":"Science"},{"key":"31379_CR6","unstructured":"WHO. Interim statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC). https:\/\/www.who.int\/news\/item\/11-01-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-advisory-group-on-covid-19-vaccine-composition (2022)."},{"key":"31379_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41421-022-00383-5","volume":"8","author":"Y Liang","year":"2022","unstructured":"Liang, Y. et al. Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. Cell Discov. 8, 17 (2022).","journal-title":"Cell Discov."},{"key":"31379_CR8","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","volume":"155","author":"DH Barouch","year":"2013","unstructured":"Barouch, D. H. et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHV challenges in rhesus monkeys. Cell 155, 531\u2013539 (2013).","journal-title":"Cell"},{"key":"31379_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.abf6840","volume":"371","author":"AA Cohen","year":"2021","unstructured":"Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 371, 735\u2013741 (2021).","journal-title":"Science"},{"key":"31379_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","volume":"20","author":"M Kanekiyo","year":"2019","unstructured":"Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol. 20, 362\u2013372 (2019).","journal-title":"Nat. Immunol."},{"key":"31379_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713\u2013721.e9 (2020).","journal-title":"Cell"},{"key":"31379_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"NA Kaabi","year":"2021","unstructured":"Kaabi, N. A. et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults. JAMA 326, 35\u201345 (2021).","journal-title":"JAMA"},{"key":"31379_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29477-0","volume":"13","author":"X Yu","year":"2022","unstructured":"Yu, X. et al. Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Nat. Commun. 13, 1788 (2022).","journal-title":"Nat. Commun."},{"key":"31379_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molimm.2022.01.009","volume":"143","author":"MN Badano","year":"2022","unstructured":"Badano, M. N. et al. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2. Mol. Immunol. 143, 94\u201399 (2022).","journal-title":"Mol. Immunol."},{"key":"31379_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/22221751.2021.2022440","volume":"11","author":"J Ai","year":"2022","unstructured":"Ai, J. et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg. Microbes Infect. 11, 337\u2013343 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"31379_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","volume":"11","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg. Microbes Infect. 11, 1\u20135 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"31379_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"31379_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-021-04387-1","volume":"602","author":"S Cele","year":"2022","unstructured":"Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654\u2013656 (2022).","journal-title":"Nature"},{"key":"31379_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia, S. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase1\/2 trial. Lancet Infect. Dis. 21, 39\u201351 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"31379_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"31379_CR21","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"31379_CR22","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, E52\u2013E61 (2022).","journal-title":"Lancet Microbe"},{"key":"31379_CR23","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMc2119426","volume":"386","author":"X Zhao","year":"2022","unstructured":"Zhao, X. et al. Effects of a prolonged booster interval on neutralization of Omicron variant. N. Engl. J. Med. 386, 894\u2013896 (2022).","journal-title":"N. Engl. J. Med."},{"key":"31379_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00432-w","volume":"7","author":"H Parry","year":"2022","unstructured":"Parry, H. et al. Extended interval BNT162b2 vaccination enhances peak antibody generation. Npj Vaccines 7, 14 (2022).","journal-title":"Npj Vaccines"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31379-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:55:14Z","timestamp":1669294514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31379-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["31379"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-31379-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.08.22272062","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"17 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.K.Y., T.Y., M.L., X.Z., C.Q., D.Y.L., Z.N.W., J.L.Y., L.Q., Y.T.Z., and X.M.Y. are employees of the China National Biotec Group Company Limited. L.F.D., S.S., Y.L., Y.K., J.G.S., Jing Zhang (NVSI), S.S.Y., X.C., Y.T., J.W.H., Z.H.L., and Q.M.L. are employees of the National Vaccine and Serum Institute (NVSI). X.J.G. and X.Y.M. are employees of Lanzhou Institute of Biological Products Company Limited (LIBP). H.W. and Jin Zhang are employees of Beijing Institute of Biological Products Company Limited (BIBP). L.F.D., S.S., Y.L., J.G.S., Jing Zhang (NVSI), J.W.H., Z.H.L., and Q.M.L. are listed as inventors of the patent applications for the recombinant trimeric RBD-based vaccines (Application numbers: 202110348881.6, 202110464788.1 and 202110676901.2). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3654"}}